A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
作者: Xinyan LiWeichen LiLingping Hou
作者单位: 1Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2Department of TCM Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
刊名: Value in Health Regional Issues, 2019, Vol.18 , pp.1-7
来源数据库: Elsevier Journal
DOI: 10.1016/j.vhri.2018.05.001
关键词: BevacizumabChemotherapyCost-effectivenessNon–small-cell lung cancer
原始语种摘要: ABSTRACT(#br)Background(#br)The first-line bevacizumab plus chemotherapy resulted in a clinical efficacy for Chinese patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). Some economic analyses have carried out various methods to evaluate the cost-effectiveness of bevacizumab as the first-line treatment for NSCLC in other countries. Our objective was to assess the cost-effectiveness of bevacizumab plus chemotherapy compared with chemotherapy alone for the first-line treatment of advanced nonsquamous NSCLC.(#br)Methods(#br)A Markov model was applied from the perspective of the Chinese health care system to assess cost-effectiveness. It was based on the clinical trial BEYOND that compared bevacizumab plus carboplatin/paclitaxel (B+CP) with placebo plus carboplatin and...
全文获取路径: Elsevier  (合作)
分享到:

×
关键词翻译
关键词翻译
  • chemotherapy 化学疗法
  • carboplatin 卡波铂
  • effectiveness 有效性
  • Cancer 巨蟹座
  • advanced 先进的
  • combined 组合
  • sensitivity 灵敏度
  • compared 肿瘤和正常组织细胞周期的比较
  • years 年代
  • trial 试验